Deerfield Management PRVA Position
ExitedDeerfield Management exited their position in Privia Health Group, Inc. (PRVA) in Q4 2024, after holding the stock for 2 quarters.
The position was first reported in Q3 2024 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds PRVA.
About Privia Health Group, Inc.
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.
Full company profile →Short Interest
3.4%
2.5 days to cover
Deerfield Management PRVA Position History
Frequently Asked Questions
Does Deerfield Management own PRVA?
No. Deerfield Management exited their position in Privia Health Group, Inc. (PRVA) in Q4 2024. They previously held the stock for 2 quarters.
How many hedge funds own PRVA?
1 specialist biotech hedge fund currently holds PRVA, including Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy PRVA?
Deerfield Management's position in PRVA was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's PRVA position increasing or decreasing?
Deerfield Management completely exited their PRVA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRVACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →